Gary Lyons Biography and Net Worth

Director of Travere Therapeutics

Gary Lyons has served as a director of Travere Therapeutics since October 2014 and chair of the company since May 2016. Previously, Mr. Lyons was the founding president and chief executive officer of Neurocrine Biosciences, Inc. and he remains a member of its board of directors. Prior to joining Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, Inc., including vice president of business development and vice president of sales. Mr. Lyons currently serves on the board of directors of Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and metabolic diseases. Previously, Mr. Lyons served on the board of directors of Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.), from May 2017 to June 2023, and on the board of directors of Fresh Tracks Therapeutics, Inc. (formerly known as Brickell Biotech, Inc.) from August 2019 to September 2023. Mr. Lyons is also a senior advisor for HealthCare Royalty Partners. Mr. Lyons holds a B.A. in marine biology from the University of New Hampshire and an MBA. from Northwestern University’s J.L. Kellogg Graduate School of Management.

What is Gary A. Lyons' net worth?: The estimated net worth of Gary A. Lyons is at least $1.01 million as of October 4th, 2024. Lyons owns 51,000 shares of Travere Therapeutics stock worth more than $1,006,230 as of March 15th. This net worth evaluation does not reflect any other assets that Lyons may own. Learn More about Gary A. Lyons' net worth.
How do I contact Gary A. Lyons?: The corporate mailing address for Lyons and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at ir@retrophin.com. Learn More on Gary A. Lyons' contact information.
Has Gary A. Lyons been buying or selling shares of Travere Therapeutics?: Gary A. Lyons has not been actively trading shares of Travere Therapeutics during the last ninety days. Most recently, Gary A. Lyons sold 40,000 shares of the business's stock in a transaction on Friday, October 4th. The shares were sold at an average price of $14.73, for a transaction totalling $589,200.00. Following the completion of the sale, the director now directly owns 51,000 shares of the company's stock, valued at $751,230. Learn More on Gary A. Lyons' trading history.
Who are Travere Therapeutics' active insiders?: Travere Therapeutics' insider roster includes Steve Aselage (Director), Roy Baynes (Director), Sandra Calvin (CAO), Laura Clague (CFO), Christopher Cline (Chief Financial Officer), Eric Dube (CEO), Peter Heerma (Insider), Jula Inrig (Insider), Gary Lyons (Director), Jeffrey Meckler (Director), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.
Are insiders buying or selling shares of Travere Therapeutics?: During the last year, insiders at the sold shares 28 times. They sold a total of 329,186 shares worth more than $6,178,934.13. The most recent insider tranaction occured on February, 12th when SVP William E Rote sold 5,200 shares worth more than $122,356.00. Insiders at Travere Therapeutics own 3.8% of the company. Learn More about insider trades at Travere Therapeutics.
Information on this page was last updated on 2/12/2025.

Gary A. Lyons Insider Trading History at Travere Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/4/2024	Sell	40,000	$14.73	$589,200.00	51,000

Gary A. Lyons Buying and Selling Activity at Travere Therapeutics

Travere Therapeutics Company Overview

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $19.73

$18.86

$19.87

50 Day Range

MA: $20.33

$17.07

$23.75

2 Week Range

Now: $19.73

$5.12

$25.29

Volume

1,137,210 shs

Average Volume

1,411,373 shs

Market Capitalization

$1.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75